OM
CTIC

Opaleye Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Opaleye Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,400,000
Closed -$1.03M – 67
2018
Q4 		$1.03M Sell
1,400,000
-150,000
-10% -$246K 0.38% 40
2018
Q3 		$3.35M Buy
1,550,000
+1,388,600
+860% +$3.44M 0.85% 32
2018
Q2 		$803K Buy
+161,400
New +$706K 0.21% 34

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Opaleye Management's CTIC Position: Q1 2019 in Review

Opaleye Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2019, closing a stake of 1,400,000 shares — an estimated $1.03M sold.

Opaleye Management first reported a position in CTIC in Q2 2018 and held it in 3 quarters. The position peaked at $3.35M in Q3 2018. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2019.

  • Opaleye Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2019 after selling out during the quarter.
  • Opaleye Management sold 1,400,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2019, an estimated $1.03M.
  • Opaleye Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 3 quarters.
  • Opaleye Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $3.35M in Q3 2018.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2019.

Based on Opaleye Management's 13F filing for Q1 2019, filed 15 May 2019.